ArticleAsian Pacific journal of cancer prevention : APJCP2025
In Vitro and In Vivo Evaluation of Rosuvastatin and Momordica charantia (Bitter Melon) Extract: Pharmacokinetic Interactions and Anticancer Potential.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigates the pharmacokinetic interactions and anticancer potential for rosuvastatin in combination with Momordica charantia (M. charantia) extract through both in vitro and in vivo models.
methodsA validated high-performance liquid chromatography (HPLC) method (R² = 0.9983) was used to quantify rosuvastatin plasma levels. In vivo pharmacokinetic parameters were assessed in Wistar rats following oral administration of rosuvastatin, M. charantia extract, and their combination. In vitro, HepG2 liver cancer cells were treated with rosuvastatin, M. charantia, and their combination to evaluate anticancer activity. The half-maximal inhibitory concentration (IC₅₀) and fractional inhibitory concentration (FIC) were calculated to assess cytotoxic effects and interaction profiles.
resultsThe IC₅₀ values were 231.7 µg/mL for M. charantia, 59.1 µg/mL for rosuvastatin, and 48.7 µg/mL for the combination, with an FIC index of 1.03, indicating additive effects. The combination enhanced anticancer efficacy by promoting apoptosis, modulating oxidative stress, and altering lipid and cholesterol metabolism in HepG2 cells. In vivo, co-administration of M. charantia significantly shortened rosuvastatin's half-life and increased its elimination rate, without affecting the maximum plasma concentration (Cmax) or the area under the plasma concentration-time curve (AUC).
conclusionThese findings suggest that M. charantia may influence rosuvastatin pharmacokinetics and enhance its anticancer effects. The study supports the potential of combining natural products with conventional pharmaceuticals as adjunctive therapies in cancer treatment while highlighting the need for further clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.